Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.70 |
| ▸ | TK1 | P04183 | 6/20 | 0.56 |
| ▸ | TK2 | O00142 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25399868 | 0.94 | RNASE1 (0.63) | RNASE1TK1TK2 | |
| SCHEMBL4808051 | 0.94 | RNASE1 (0.63) | RNASE1TK1TK2 | |
| SCHEMBL25764517 | 0.94 | RNASE1 (0.63) | RNASE1TK1TK2 | |
| SCHEMBL25400848 | 0.94 | RNASE1 (0.63) | RNASE1TK1TK2 | |
| SCHEMBL4808054 | 0.94 | RNASE1 (0.63) | RNASE1TK1TK2 | |
| SCHEMBL7746814 | 0.90 | RNASE1 (0.57) | RNASE1TK1TK2 | |
| SCHEMBL7746817 | 0.90 | RNASE1 (0.57) | RNASE1TK1TK2 | |
| SCHEMBL25399323 | 0.89 | LMNA (0.62) | RNASE1TK1TK2LMNATSHR | |
| SCHEMBL8357811 | 0.88 | RNASE1 (0.54) | RNASE1TK1TK2 | |
| SCHEMBL30396378 | 0.87 | RNASE1 (0.54) | RNASE1TK1TK2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900301-B2 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030045705-A1 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| EP-0586570-B1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS INC (US) | 2000-09-13 | — | — | EP | disclosed |
| EP-1004593-A2 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-0611075-B1 | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | SANKYO CO (JP) | 1996-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045705-A1 | Backbone modified oligonucleotide analogues | RNASE1, RNGTT, NSUN2 | RNASE1 1/4885TK1 98/4885TK2 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.